a Department of Gynecology and Obstetrics , West China Second University Hospital, Sichuan University , Chengdu , China.
b Key Laboratory of Birth Defects and Related Diseases of Women and Children , Ministry of Education , Chengdu , China.
Expert Rev Mol Diagn. 2018 Apr;18(4):371-383. doi: 10.1080/14737159.2018.1457436. Epub 2018 Mar 27.
Ovarian cancer (OC) is one of the leading causes of cancer-related death in women. Accumulating evidence showed an evolving role of HE4 in monitoring the progression and prognosis of OC but without a comprehensive analysis for prognosis and survival data. Areas covered: The present meta-analysis aims to explore the association of HE4 with survival and the clinicopathological features of OC patients. PubMed, Embase, Web of Science and the China National Knowledge Infrastructure (CNKI) were searched for relevant studies regarding the role of both serum and tissue HE4 expression in ovarian cancer. Expert commentary: HE4 has been proposed as the most promising biomarker that may complement the CA125 expression and has been approved by the FDA in monitoring the follow-up and relapse of OC patients. Our results are in accordance with the most recent evidence suggesting its important role in the prognostic surveillance of OC and a better performance in the early prediction of OC recurrence than CA125.
卵巢癌 (OC) 是导致女性癌症相关死亡的主要原因之一。越来越多的证据表明 HE4 在监测 OC 的进展和预后方面发挥着作用,但缺乏对预后和生存数据的综合分析。
本荟萃分析旨在探讨 HE4 与 OC 患者生存和临床病理特征的关系。检索了PubMed、Embase、Web of Science 和中国国家知识基础设施 (CNKI) 中关于血清和组织 HE4 表达在卵巢癌中的作用的相关研究。
HE4 已被提议作为最有前途的生物标志物,可能补充 CA125 的表达,并已获得 FDA 批准用于监测 OC 患者的随访和复发。我们的结果与最近的证据一致,表明它在 OC 的预后监测中具有重要作用,并且在早期预测 OC 复发方面比 CA125 表现更好。